Danaher Corp (DHR) 87.15 $DHR
3M Closes Ivera Acquisition to Augment Healthcare Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 4:23PM CDT
Diversified conglomerate 3M Company (MMM) recently completed the acquisition of Ivera Medical Corp -- a manufacturer of healthcare products -- for an undisclosed amount.
MMM: 166.49 (+0.83), CODI: 16.94 (+0.27), DHR: 87.15 (+0.14)
Raven Industries Downgraded to Strong Sell on Weak Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 4:20PM CDT
On Mar 14, Zacks Investment Research downgraded Raven Industries Inc. (RAVN) to a Zacks Rank #5 (Strong Sell).
CODI: 16.94 (+0.27), RAVN: 21.50 (+0.71), DHR: 87.15 (+0.14)
Flowserve Prices Senior Notes to Boost Liquidity Position - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 1:10PM CDT
In order to reduce its debt level, Flowserve Corp. (FLS) disclosed the pricing of its 1.250% senior notes worth ???500 million.
JPM: 61.75 (+0.55), FLS: 57.60 (+0.32), BAC: 15.84 (+0.23), DHR: 87.15 (+0.14)
General Electric, Kemira Partner to Provide Water Solutions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 10:10AM CDT
GE Power & Water a part of General Electric Company (GE) recently announced a distribution agreement with global chemicals company Kemira to bring the latest water technology to the pulp and paper industry.
CODI: 16.94 (+0.27), GE: 25.40 (+0.07), DHR: 87.15 (+0.14)
Tracking The Sequoia Fund - Q4 2014
V is for Value - at Seeking Alpha - Thu Mar 12, 10:07AM CDT
WST: 57.91 (+1.15), VRX: 204.26 (+2.17), AAP: 151.91 (+2.72), CAB: 58.11 (-0.06), WMT: 83.24 (+1.72), CNQ: 29.60 (+0.86), DHR: 87.15 (+0.14), PCP: 210.16 (+2.18), GOOG: 560.36 (+2.37), FAST: 42.30 (-0.17), TRMB: 25.92 (+0.73), INT: 56.45 (+0.66), IBM: 162.88 (+3.07), COST: 152.59 (+1.28), GOOGL: 564.95 (+1.28), EME: 46.65 (+1.47), MA: 89.82 (+0.80), JEC: 44.80 (+0.81), ORLY: 214.79 (-0.18), TIF: 82.93 (-3.44), WAT: 124.82 (+1.21), ZTS: 47.34 (-0.07), OMC: 78.31 (+0.08), BRO: 33.13 (+0.30), VRSK: 71.50 (-0.05), GS: 193.13 (+3.16), TJX: 69.47 (+1.31), MHK: 181.03 (+1.16), EXPD: 49.27 (+0.40), RBA: 25.50 (+0.46), IDXX: 152.80 (-1.65), PX: 121.92 (-0.09), BRK.B: 145.53 (+0.65), BRK.A: 218,300.00 (+300.00)
Raven Industries Misses Q4 Earnings on Higher Expenses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 9:00AM CDT
Raven's (RAVN) fourth-quarter earnings declined year over year and missed the Zacks Consensus Estimate.
CODI: 16.94 (+0.27), AGCO: 47.58 (+0.26), RAVN: 21.50 (+0.71), DHR: 87.15 (+0.14)
Raven Industries Slumps: RAVN Falls 6.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 7:38AM CDT
Raven Industries saw a big move last session, as the company’s shares fell nearly 7% on the day.
DHR: 87.15 (+0.14), RAVN: 21.50 (+0.71)
Pratt & Whitney to Raise Price of Geared Turbofan Engines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 9:50AM CDT
Pratt & Whitney, a division of United Technologies Corp (UTX), recently announced its intention to increase the price of its fuel-efficient PurePower Geared Turbofan (GTF) engines across its product line effective this year.
CODI: 16.94 (+0.27), UTX: 119.46 (+0.08), DHR: 87.15 (+0.14)
Global Glycated Hemoglobin Testing Market 2015-2019
M2 - Tue Mar 10, 7:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f7rht/global_glycated) has announced the addition of the "Global Glycated Hemoglobin Testing Market 2015-2019" report to their offering. The Global Glycated Hemoglobin Testing market to grow at a CAGR of 10.22% over the period 2014-2019. This report covers the present scenario and the growth prospects of Global Glycated Hemoglobin Testing market for the period 2015-2019. Glycated hemoglobin helps measure the concentration of glucose in the blood of an individual. HbA1c, a specific chemical form of glycated hemoglobin, is used to determine a person's average blood glucose level over a period. It is a standardized test recommended by doctors for the diagnosis of type 2 diabetes or to test the control level of the blood glucose. The testing can be done in a laboratory or at a POC center. Different types of technologies, such as chromatography, immunoassay, capillary electrophoresis, direct enzymatic assay, and micro-optical detection method, are used in HbA1c testing. One key trend upcoming in this market is the increased adoption of POC HbA1c testing. Rapid result outcomes and faster treatment decisions have increased the use of POC HbA1c testing for measuring blood glucose. According to the report, the growth of the Global Glycated Hemoglobin Testing market is predominantly driven by the growing incidence of diabetes in the world. An increase in the aging population, sedentary lifestyles, increasing obesity, and inappropriate dietary habits can lead to chronic diseases that foster the demand for HbA1c testing. Further, the report states that the availability of substitute tests, such as test strips, glucose meters, lancets, and continuous blood glucose meters, poses a serious threat to the use of HbA1c testing. To calculate the market size, the report considers revenue generated from the sales of HbA1c products, including - Laboratory HbA1c testing products - POC HbA1c testing products - Based on technology, the market can be characterized into the following segments: - Chromatography - Immunoassay - Others (Capillary Electrophoresis, Direct Enzymatic Assay, and Micro-optical Detection Method) Key Vendors - Abbott Laboratories - Alere - Danaher - F. Hoffmann-La Roche Other Prominent Vendors - Arkray - Bayer - Bio-Rad Laboratories - Ceragem Medisys - Chek Diagnostics - Daiichi Biotech - DiaSys Diagnostic Systems - Diazyme Laboratories - EKF Diagnostics - Erba Mannheim - Human Diagnostics - Lite-On Technology - Menarini - Mindray Medical - Randox Laboratories - Sebia - Siemens Healthcare - TaiDoc Technology - Tosoh Bioscience - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/9f...l_glycated
ABT: 47.47 (+0.03), TRIB: 19.39 (+0.45), DHR: 87.15 (+0.14)
GE Ventures-Stanford Health Care Collaborate, Shares Dip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 4:10PM CDT
GE Ventures, a part of General Electric Company (GE), and health care firm Stanford Health Care recently announced the launch of Evidation Health, an organisation committed to improving health outcomes with evidence-based digital medicine
CODI: 16.94 (+0.27), GE: 25.40 (+0.07), DHR: 87.15 (+0.14)
Should General Electric (GE) Be in Your Portfolio Now? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 3:45PM CDT
On Mar 7, Zacks Investment Research upgraded leading diversified conglomerate General Electric Company (GE) to a Zacks Rank #3 (Hold) from a Zacks Rank #4 (Sell).
CODI: 16.94 (+0.27), GE: 25.40 (+0.07), RBC: 79.96 (+0.46), DHR: 87.15 (+0.14)
Will Raven Industries (RAVN) Miss Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 10:00AM CDT
Raven (RAVN) will report fourth-quarter fiscal 2015 results on Mar 11.
HON: 105.40 (+2.38), RAVN: 21.50 (+0.71), DHR: 87.15 (+0.14), GOOG: 560.36 (+2.37)
General Electric CEO Immelt to Resign - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 4:10PM CST
Investors of General Electric Company (GE) are geared up for a change in its CEO.
CODI: 16.94 (+0.27), GE: 25.40 (+0.07), DHR: 87.15 (+0.14), AAPL: 125.90 (-1.60)
These Stocks Just Raised Their Dividends
Eric Volkman, The Motley Fool - Motley Fool - Fri Mar 06, 3:04PM CST
Last week was another solid one for dividend raises. Nearly all major sectors of the economy were represented -- a very encouraging sign -- and more than a few of those hikes were well in double-digit percentage territory. It was hard to choose...
HD: 117.49 (+2.33), DHR: 87.15 (+0.14), WM: 54.55 (-0.18)
United Technologies' Sikorsky's iPad App for S-76D Copters - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 9:40AM CST
Sikorsky Aircraft Corp., a subsidiary of United Technologies Corp. (UTX), recently announced an iPad application to offer support for S-76D helicopters.
FSS: 16.02 (+0.27), UTX: 119.46 (+0.08), DHR: 87.15 (+0.14)
5 Bullish Reasons to Buy Danaher Corporation (DHR) Stock
Lee Samaha, The Motley Fool - Motley Fool - Wed Mar 04, 8:12AM CST
It's been a curious sort of year for Danaher investors as they watched the stock underperform the S&P 500 for much of 2014, only to come roaring back toward the end of the year. In fact, in the last six months, the stock rose 13.2% versus...
DHR: 87.15 (+0.14)
GE's Milestone Aviation Announces Global Expansion Plans - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 4:54PM CST
Milestone Aviation Group, a GE Capital Aviation Services company (GECAS) that is a part of General Electric Company (GE), recently announced its major expansion plans.
GE: 25.40 (+0.07), FSS: 16.02 (+0.27), DHR: 87.15 (+0.14)
Global POC Diagnostics Market 2015-2019 - High Prevalence of Diabetes and Obesity & Rapid Adoption of POC Diagnostic Tests
M2 - Tue Mar 03, 8:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/bngrb9/global_poc) has announced the addition of the "Global POC Diagnostics Market 2015-2019" report to their offering. The analysts forecast the Global POC Diagnostics market to grow at a CAGR of 8.47 percent over the period 2014-2019. POC diagnostics are IVD devices and tools used for diagnosing diseases in patients outside a clinical laboratory setting. The use of these devices helps in the rapid diagnosis of the medical conditions and aids in providing appropriate treatments and medication to patients. Rapid adoption of POC diagnostic tests is one of the key trends upcoming in this market. The use of POC diagnostics has been increasing over the past years as they provide rapid results and aid in immediate treatment decisions. This reduces the hospital stay of patients and delay in test results because of overcrowded emergency wards. According to the report, high prevalence of diabetes and obesity among patients worldwide is one major driver of the market. Unhealthy lifestyles and a lack of exercise result in a higher incidence of chronic diseases in people, which has increased the demand for POC diagnostics. Further, the report states that limitation of POC diagnostics is a major challenge that the market faces. The limited lifespan of the biomolecules and complications with quality control can restrict the use of POC diagnostics. To calculate the market size, the report considers revenue generated from the sales of POC diagnostics used in various applications: - Blood glucose testing - Infectious diseases testing - Cardiac markers testing - Coagulation testing - Pregnancy and fertility testing - Blood gas/electrolytes testing - Tumor markers testing - Urinalysis testing - Cholesterol testing Key Vendors - Abbott Laboratories - Alere - Bayer Healthcare - Danaher - F. Hoffmann-La Roche - Johnson & Johnson Other Prominent Vendors - A. Menarini Diagnostics - Abaxis - Acon - BD - Bio-Rad Laboratories - Chembio Diagnostics - Chongqing Haray International Business - Clarity Diagnostics - Clinical Innovations - Contec Medical - Eurotrol - Fudakang Ind'l - Helena Laboratories - i-sens - International Technidyne - Medtronic - Nipro Diagnostics - Nova Biomedical - OraSure Technologies - Phamatech - Quidel - Radiometer Medical - Randox Laboratories - SA Scientific - Sekisui Diagnostics - Shenzhen Fitconn Technology - Siemens Healthcare - STAT Technologies - Streck - TaiDoc For more information visit http://www.researchandmarkets.com/research/bngrb9/global_poc
JNJ: 102.40 (+0.71), ABT: 47.47 (+0.03), MDT: 78.02 (+0.36), ABAX: 65.61 (+1.33), DHR: 87.15 (+0.14), CEMI: 4.20 (+0.05), OSUR: 7.30 (+0.08)
Leucadia (LUK) Reports Loss in Q4; Revenues Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 8:00AM CST
Leucadia National Corporation (LUK) reported loss of 1 cent per share in fourth-quarter 2014 compared with earnings of 5 cents per share in the year-ago quarter. Net revenue was $2,688.4 million, down 8% year over year.
LUK: 23.05 (-0.02), FSS: 16.02 (+0.27), DHR: 87.15 (+0.14)
EMCOR (EME) Lags Q4 Earnings, Shares Marginally Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 9:12AM CST
Shares of leading mechanical & electrical construction and energy infrastructure service provider EMCOR Group, Inc. (EME) inched down 1.54% after it reported fourth-quarter 2014 results.
DHR: 87.15 (+0.14), EME: 46.65 (+1.47), DY: 46.96 (-0.13), AOS: 64.51 (+0.26)
3M Closes Ivera Acquisition to Augment Healthcare Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 4:23PM CDT
Diversified conglomerate 3M Company (MMM) recently completed the acquisition of Ivera Medical Corp -- a manufacturer of healthcare products -- for an undisclosed amount.
MMM: 166.49 (+0.83), CODI: 16.94 (+0.27), DHR: 87.15 (+0.14)
Raven Industries Downgraded to Strong Sell on Weak Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 4:20PM CDT
On Mar 14, Zacks Investment Research downgraded Raven Industries Inc. (RAVN) to a Zacks Rank #5 (Strong Sell).
CODI: 16.94 (+0.27), RAVN: 21.50 (+0.71), DHR: 87.15 (+0.14)
Flowserve Prices Senior Notes to Boost Liquidity Position - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 1:10PM CDT
In order to reduce its debt level, Flowserve Corp. (FLS) disclosed the pricing of its 1.250% senior notes worth ???500 million.
JPM: 61.75 (+0.55), FLS: 57.60 (+0.32), BAC: 15.84 (+0.23), DHR: 87.15 (+0.14)
General Electric, Kemira Partner to Provide Water Solutions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 10:10AM CDT
GE Power & Water a part of General Electric Company (GE) recently announced a distribution agreement with global chemicals company Kemira to bring the latest water technology to the pulp and paper industry.
CODI: 16.94 (+0.27), GE: 25.40 (+0.07), DHR: 87.15 (+0.14)
Tracking The Sequoia Fund - Q4 2014
V is for Value - at Seeking Alpha - Thu Mar 12, 10:07AM CDT
WST: 57.91 (+1.15), VRX: 204.26 (+2.17), AAP: 151.91 (+2.72), CAB: 58.11 (-0.06), WMT: 83.24 (+1.72), CNQ: 29.60 (+0.86), DHR: 87.15 (+0.14), PCP: 210.16 (+2.18), GOOG: 560.36 (+2.37), FAST: 42.30 (-0.17), TRMB: 25.92 (+0.73), INT: 56.45 (+0.66), IBM: 162.88 (+3.07), COST: 152.59 (+1.28), GOOGL: 564.95 (+1.28), EME: 46.65 (+1.47), MA: 89.82 (+0.80), JEC: 44.80 (+0.81), ORLY: 214.79 (-0.18), TIF: 82.93 (-3.44), WAT: 124.82 (+1.21), ZTS: 47.34 (-0.07), OMC: 78.31 (+0.08), BRO: 33.13 (+0.30), VRSK: 71.50 (-0.05), GS: 193.13 (+3.16), TJX: 69.47 (+1.31), MHK: 181.03 (+1.16), EXPD: 49.27 (+0.40), RBA: 25.50 (+0.46), IDXX: 152.80 (-1.65), PX: 121.92 (-0.09), BRK.B: 145.53 (+0.65), BRK.A: 218,300.00 (+300.00)
Raven Industries Misses Q4 Earnings on Higher Expenses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 9:00AM CDT
Raven's (RAVN) fourth-quarter earnings declined year over year and missed the Zacks Consensus Estimate.
CODI: 16.94 (+0.27), AGCO: 47.58 (+0.26), RAVN: 21.50 (+0.71), DHR: 87.15 (+0.14)
Raven Industries Slumps: RAVN Falls 6.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 7:38AM CDT
Raven Industries saw a big move last session, as the company’s shares fell nearly 7% on the day.
DHR: 87.15 (+0.14), RAVN: 21.50 (+0.71)
Pratt & Whitney to Raise Price of Geared Turbofan Engines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 9:50AM CDT
Pratt & Whitney, a division of United Technologies Corp (UTX), recently announced its intention to increase the price of its fuel-efficient PurePower Geared Turbofan (GTF) engines across its product line effective this year.
CODI: 16.94 (+0.27), UTX: 119.46 (+0.08), DHR: 87.15 (+0.14)
Global Glycated Hemoglobin Testing Market 2015-2019
M2 - Tue Mar 10, 7:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f7rht/global_glycated) has announced the addition of the "Global Glycated Hemoglobin Testing Market 2015-2019" report to their offering. The Global Glycated Hemoglobin Testing market to grow at a CAGR of 10.22% over the period 2014-2019. This report covers the present scenario and the growth prospects of Global Glycated Hemoglobin Testing market for the period 2015-2019. Glycated hemoglobin helps measure the concentration of glucose in the blood of an individual. HbA1c, a specific chemical form of glycated hemoglobin, is used to determine a person's average blood glucose level over a period. It is a standardized test recommended by doctors for the diagnosis of type 2 diabetes or to test the control level of the blood glucose. The testing can be done in a laboratory or at a POC center. Different types of technologies, such as chromatography, immunoassay, capillary electrophoresis, direct enzymatic assay, and micro-optical detection method, are used in HbA1c testing. One key trend upcoming in this market is the increased adoption of POC HbA1c testing. Rapid result outcomes and faster treatment decisions have increased the use of POC HbA1c testing for measuring blood glucose. According to the report, the growth of the Global Glycated Hemoglobin Testing market is predominantly driven by the growing incidence of diabetes in the world. An increase in the aging population, sedentary lifestyles, increasing obesity, and inappropriate dietary habits can lead to chronic diseases that foster the demand for HbA1c testing. Further, the report states that the availability of substitute tests, such as test strips, glucose meters, lancets, and continuous blood glucose meters, poses a serious threat to the use of HbA1c testing. To calculate the market size, the report considers revenue generated from the sales of HbA1c products, including - Laboratory HbA1c testing products - POC HbA1c testing products - Based on technology, the market can be characterized into the following segments: - Chromatography - Immunoassay - Others (Capillary Electrophoresis, Direct Enzymatic Assay, and Micro-optical Detection Method) Key Vendors - Abbott Laboratories - Alere - Danaher - F. Hoffmann-La Roche Other Prominent Vendors - Arkray - Bayer - Bio-Rad Laboratories - Ceragem Medisys - Chek Diagnostics - Daiichi Biotech - DiaSys Diagnostic Systems - Diazyme Laboratories - EKF Diagnostics - Erba Mannheim - Human Diagnostics - Lite-On Technology - Menarini - Mindray Medical - Randox Laboratories - Sebia - Siemens Healthcare - TaiDoc Technology - Tosoh Bioscience - Trinity Biotech For more information visit http://www.researchandmarkets.com/research/9f...l_glycated
ABT: 47.47 (+0.03), TRIB: 19.39 (+0.45), DHR: 87.15 (+0.14)
GE Ventures-Stanford Health Care Collaborate, Shares Dip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 4:10PM CDT
GE Ventures, a part of General Electric Company (GE), and health care firm Stanford Health Care recently announced the launch of Evidation Health, an organisation committed to improving health outcomes with evidence-based digital medicine
CODI: 16.94 (+0.27), GE: 25.40 (+0.07), DHR: 87.15 (+0.14)
Should General Electric (GE) Be in Your Portfolio Now? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 3:45PM CDT
On Mar 7, Zacks Investment Research upgraded leading diversified conglomerate General Electric Company (GE) to a Zacks Rank #3 (Hold) from a Zacks Rank #4 (Sell).
CODI: 16.94 (+0.27), GE: 25.40 (+0.07), RBC: 79.96 (+0.46), DHR: 87.15 (+0.14)
Will Raven Industries (RAVN) Miss Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 10:00AM CDT
Raven (RAVN) will report fourth-quarter fiscal 2015 results on Mar 11.
HON: 105.40 (+2.38), RAVN: 21.50 (+0.71), DHR: 87.15 (+0.14), GOOG: 560.36 (+2.37)
General Electric CEO Immelt to Resign - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 4:10PM CST
Investors of General Electric Company (GE) are geared up for a change in its CEO.
CODI: 16.94 (+0.27), GE: 25.40 (+0.07), DHR: 87.15 (+0.14), AAPL: 125.90 (-1.60)
These Stocks Just Raised Their Dividends
Eric Volkman, The Motley Fool - Motley Fool - Fri Mar 06, 3:04PM CST
Last week was another solid one for dividend raises. Nearly all major sectors of the economy were represented -- a very encouraging sign -- and more than a few of those hikes were well in double-digit percentage territory. It was hard to choose...
HD: 117.49 (+2.33), DHR: 87.15 (+0.14), WM: 54.55 (-0.18)
United Technologies' Sikorsky's iPad App for S-76D Copters - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 05, 9:40AM CST
Sikorsky Aircraft Corp., a subsidiary of United Technologies Corp. (UTX), recently announced an iPad application to offer support for S-76D helicopters.
FSS: 16.02 (+0.27), UTX: 119.46 (+0.08), DHR: 87.15 (+0.14)
5 Bullish Reasons to Buy Danaher Corporation (DHR) Stock
Lee Samaha, The Motley Fool - Motley Fool - Wed Mar 04, 8:12AM CST
It's been a curious sort of year for Danaher investors as they watched the stock underperform the S&P 500 for much of 2014, only to come roaring back toward the end of the year. In fact, in the last six months, the stock rose 13.2% versus...
DHR: 87.15 (+0.14)
GE's Milestone Aviation Announces Global Expansion Plans - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 4:54PM CST
Milestone Aviation Group, a GE Capital Aviation Services company (GECAS) that is a part of General Electric Company (GE), recently announced its major expansion plans.
GE: 25.40 (+0.07), FSS: 16.02 (+0.27), DHR: 87.15 (+0.14)
Global POC Diagnostics Market 2015-2019 - High Prevalence of Diabetes and Obesity & Rapid Adoption of POC Diagnostic Tests
M2 - Tue Mar 03, 8:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/bngrb9/global_poc) has announced the addition of the "Global POC Diagnostics Market 2015-2019" report to their offering. The analysts forecast the Global POC Diagnostics market to grow at a CAGR of 8.47 percent over the period 2014-2019. POC diagnostics are IVD devices and tools used for diagnosing diseases in patients outside a clinical laboratory setting. The use of these devices helps in the rapid diagnosis of the medical conditions and aids in providing appropriate treatments and medication to patients. Rapid adoption of POC diagnostic tests is one of the key trends upcoming in this market. The use of POC diagnostics has been increasing over the past years as they provide rapid results and aid in immediate treatment decisions. This reduces the hospital stay of patients and delay in test results because of overcrowded emergency wards. According to the report, high prevalence of diabetes and obesity among patients worldwide is one major driver of the market. Unhealthy lifestyles and a lack of exercise result in a higher incidence of chronic diseases in people, which has increased the demand for POC diagnostics. Further, the report states that limitation of POC diagnostics is a major challenge that the market faces. The limited lifespan of the biomolecules and complications with quality control can restrict the use of POC diagnostics. To calculate the market size, the report considers revenue generated from the sales of POC diagnostics used in various applications: - Blood glucose testing - Infectious diseases testing - Cardiac markers testing - Coagulation testing - Pregnancy and fertility testing - Blood gas/electrolytes testing - Tumor markers testing - Urinalysis testing - Cholesterol testing Key Vendors - Abbott Laboratories - Alere - Bayer Healthcare - Danaher - F. Hoffmann-La Roche - Johnson & Johnson Other Prominent Vendors - A. Menarini Diagnostics - Abaxis - Acon - BD - Bio-Rad Laboratories - Chembio Diagnostics - Chongqing Haray International Business - Clarity Diagnostics - Clinical Innovations - Contec Medical - Eurotrol - Fudakang Ind'l - Helena Laboratories - i-sens - International Technidyne - Medtronic - Nipro Diagnostics - Nova Biomedical - OraSure Technologies - Phamatech - Quidel - Radiometer Medical - Randox Laboratories - SA Scientific - Sekisui Diagnostics - Shenzhen Fitconn Technology - Siemens Healthcare - STAT Technologies - Streck - TaiDoc For more information visit http://www.researchandmarkets.com/research/bngrb9/global_poc
JNJ: 102.40 (+0.71), ABT: 47.47 (+0.03), MDT: 78.02 (+0.36), ABAX: 65.61 (+1.33), DHR: 87.15 (+0.14), CEMI: 4.20 (+0.05), OSUR: 7.30 (+0.08)
Leucadia (LUK) Reports Loss in Q4; Revenues Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 8:00AM CST
Leucadia National Corporation (LUK) reported loss of 1 cent per share in fourth-quarter 2014 compared with earnings of 5 cents per share in the year-ago quarter. Net revenue was $2,688.4 million, down 8% year over year.
LUK: 23.05 (-0.02), FSS: 16.02 (+0.27), DHR: 87.15 (+0.14)
EMCOR (EME) Lags Q4 Earnings, Shares Marginally Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 9:12AM CST
Shares of leading mechanical & electrical construction and energy infrastructure service provider EMCOR Group, Inc. (EME) inched down 1.54% after it reported fourth-quarter 2014 results.
DHR: 87.15 (+0.14), EME: 46.65 (+1.47), DY: 46.96 (-0.13), AOS: 64.51 (+0.26)
